## AMENDMENTS TO THE CLAIMS

- 1. 7. (Canceled)
- 8. (Currently Amended) A method for expressing long-term potentiation of synaptic transmission, comprising administering to a patient in need thereof an effective amount of a compound

$$R^4$$
— $Z$ — $N$ — $J$ — $Q$ — $R^7$ 

wherein

R<sup>4</sup> is lower alkanoyl,

R<sup>7</sup> is phenyl substituted with halogen,

Z is a single bond,

J is –NH-, and

Q is -CO-,

or pharmaceutically acceptable salts thereof.

- 9. 12. (Canceled)
- 13. (Previously Presented) The method for expressing long-term potentiation of synaptic transmission of claim 8, which is a method for the prophylaxis or treatment of one or more cerebral diseases.
- 14. (Previously Presented) The method for expressing long-term potentiation of synaptic transmission of claim 13, wherein said cerebral disease is dementia or amnesia.
  - 15. 30. (Canceled)
- 31. (Currently Amended) A method for screening an agent for expression of longterm potentiation of synaptic transmission, which comprises stimulating hippocampal slices,

bringing a hippocampal slice into contact with a test compound having the following formula:

$$R^4$$
— $Z$ — $N$ — $J$ — $Q$ — $R^7$ 

wherein

7

R<sup>4</sup> is lower alkanoyl,

R<sup>7</sup> is phenyl substituted with halogen,

Z is a single bond,

J is –NH-, and

Q is -CO-,

or pharmaceutically acceptable salts thereof,

measuring an amount of somatostatin released from the hippocampal slice and/or a release time thereof, measuring an amount of somatostatin released from a hippocampal slice and/or a release time thereof in the absence of a contact with the test compound, and comparing the amounts and/or the times to calculate the amount of somatostatin released from the hippocampal slice and/or the release time thereof caused by the contact with the test compound.

- 32. (Original) The screening method according to claim 31, which is a screening method of an anti-dementia agent or anti-amnesia agent.
  - 33. (Canceled)
- 34. (Previously Presented) A method for expressing long-term potentiation of synaptic transmission, comprising administering to a patient in need thereof an effective amount of a compound obtained by the screening method of claim 31.
  - 35. (Canceled)

- 36. (Previously Presented) A pharmaceutical composition for expression of long-term potentiation of synaptic transmission which comprises a compound obtained by the screening method of claim 31 and a pharmaceutically acceptable carrier or excipient.
  - 37. (Canceled)

3

- 38. (Previously Presented) A compound selected by the screening method of claim31.
  - 39. 55. (Canceled)
- 56. (Previously Presented) The method of claim 8, wherein said compound is N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide.